Collplant Biotechnologies Ltd. (CLGN): Modelo de negócios Canvas [Jan-2025 Atualizado]

No mundo de ponta da medicina regenerativa, a Collplant Biotechnologies Ltd. (CLGN) surge como um inovador inovador, revolucionando a engenharia de tecidos por meio de sua tecnologia exclusiva de impressão. Ao aproveitar o poder do colágeno humano recombinante, esta empresa pioneira está transformando como os profissionais médicos abordam a regeneração tecidual, oferecendo soluções inovadoras que preenchem a lacuna entre imaginação científica e realidade clínica. Seu sofisticado modelo de negócios representa uma interseção atraente de biotecnologia, inovação médica e parcerias estratégicas que poderiam potencialmente remodelar o futuro da medicina regenerativa.

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negócios: Parcerias -chave

Empresas de dispositivos farmacêuticos e médicos

A Collplant estabeleceu as principais parcerias com as seguintes empresas de dispositivos farmacêuticos e médicos:

Empresa parceira	Foco de colaboração	Ano estabelecido
Novartis	Soluções de tecido regenerativo 3D bioprinhas	2021
Terapêutica Unida	Tecnologias de regeneração pulmonar	2022

Instituições de pesquisa acadêmica

Collplant colabora com instituições acadêmicas para promover o desenvolvimento de biotecnologia:

• Technion - Instituto de Tecnologia de Israel
• Universidade de Tel Aviv
• Universidade Ben-Gurion de Negev

Fabricantes de equipamentos médicos

Parcerias estratégicas com os fabricantes de equipamentos médicos incluem:

Fabricante	Tipo de colaboração	Foco em tecnologia
Stratasys	Desenvolvimento de tecnologia de bioprinting 3D	Engenharia de tecidos regenerativos

Investidores estratégicos e capital de risco

Principais parcerias e investimentos financeiros da Collplant:

Investidor	Valor do investimento	Ano
Consultores orbimed	US $ 15,3 milhões	2022
Capital de risco Pontifax	US $ 12,7 milhões	2021

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologia de bio-impressão proprietária para regeneração de tecidos

A Collplant utiliza a plataforma de tecnologia recombinante de colágeno humano (RHCollagen) baseado em plantas. A partir de 2023, a empresa desenvolveu três plataformas de tecnologia de impressão primária:

• Bioinks para aplicações de bioprinting 3D
• Soluções de Medicina Regenerativa
• Produtos médicos derivados de tecidos

Plataforma de tecnologia	Estágio de desenvolvimento	Status de patente
RhCollagen Bioink	Comercializado	Múltiplas patentes internacionais
Tecnologia de bioprinting 3D	Pesquisa avançada	8 patentes concedidas

Realização de pesquisas e ensaios clínicos para medicina regenerativa avançada

O Collplant se concentra na pesquisa de medicina regenerativa em várias áreas terapêuticas.

• Aplicações ortopédicas
• Tecnologias de cicatrização de feridas
• Reconstrução de tecidos moles

Área de pesquisa	Ensaios clínicos ativos	Fase atual
Reconstrução mamária	2 ensaios em andamento	Fase II/III
Cicatrização de feridas	1 teste ativo	Fase II

Manufatura recombinante em produtos médicos baseados em colágeno humano

Recursos de fabricação:

• Sistema de expressão de base de plantas proprietária
• Instalações de produção compatíveis com GMP
• Processo de fabricação escalável

Categoria de produto	Capacidade de produção anual	Segmento de mercado
Produtos Bioink	500 kg por ano	3D Bioprinting
Produtos de Medicina Regenerativa	250 kg por ano	Dispositivos médicos

Buscar proteção de propriedade intelectual e desenvolvimento de patentes

A Collplant mantém uma estratégia de propriedade intelectual robusta.

Categoria de patentes	Total de patentes	Cobertura geográfica
Patentes concedidas	21 patentes	Estados Unidos, Europa, Japão
Aplicações de patentes pendentes	12 APLICAÇÕES	Múltiplas jurisdições

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negócios: Recursos -chave

Tecnologia patenteada de plataforma de bio-impressão baseada em colágeno

Especificos de tecnologia:

Categoria de patentes	Número de patentes	Foco em tecnologia
Plataforma de bio-impressão	7 patentes principais	Aplicações de medicina regenerativa
Produção de colágeno	3 patentes proprietárias	Colágeno recombinante à base de plantas

Equipe especializada de pesquisa e desenvolvimento de biotecnologia

Composição da equipe:

• Pessoal total de P&D: 24 especialistas
• Titulares de doutorado: 12 pesquisadores
• Experiência média da indústria: 8,5 anos
• Áreas de foco de pesquisa:
  • Medicina Regenerativa
  • Tecnologias de bio-impressão 3D
  • Engenharia de tecidos

Instalações avançadas de laboratório e fabricação

Tipo de instalação	Tamanho	Localização	Capacidade
Laboratório de Pesquisa	1.200 metros quadrados	Ness Ziona, Israel	Pesquisa avançada de biotecnologia
Instalação de fabricação	800 metros quadrados	Ness Ziona, Israel	Produção bio-impressão

Portfólio de propriedade intelectual extensa

Breakdown do portfólio IP:

Categoria IP	Número total	Patentes concedidas	Aplicações pendentes
Medicina Regenerativa	15	10	5
Tecnologia de impressão biológica	12	8	4

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negócios: proposições de valor

Soluções inovadoras de impressão biológica para regeneração de tecidos e órgãos

A tecnologia de bio-impressão proprietária da Collplant, utilizando a plataforma recombinante de colágeno humano, permite soluções precisas de tecido e regeneração de órgãos.

Métrica de tecnologia	Especificação
Capacidade de produção de tinta bio	Até 500 gramas por lote
Precisão de regeneração do tecido	Precisão no nível de mícrons
Método de produção de colágeno	Extração de plantas de tabaco transgênica

Produtos médicos avançados que atendem às necessidades clínicas não atendidas

A CollLlant desenvolve produtos de medicina regenerativa direcionando desafios médicos específicos.

• Tecnologias de cicatrização de feridas
• Soluções de implantes ortopédicos
• Materiais de reconstrução mamária

Categoria de produto	Potencial de mercado	Estágio de desenvolvimento
Matrizes de cicatrização de feridas	Tamanho do mercado de US $ 2,1 bilhões	Aprovado pela FDA
Implantes ortopédicos	Tamanho do mercado de US $ 7,8 bilhões	Ensaios clínicos

Tecnologias de Medicina Regenerativa Sustentável e Biocompatível

A abordagem sustentável da Collplant aproveita a produção de colágeno baseada em plantas.

• Fabricação ecológica
• Dependência material reduzida de animal
• Pegada de carbono de baixa produção

Abordagens de engenharia de tecidos com boa relação custo-benefício

A tecnologia da Collplant permite soluções de regeneração de tecidos economicamente viáveis.

Métrica de custo	Valor
Custo de produção por grama de colágeno	$45-$60
Potencial de escalabilidade	Aumento de 300% em 3 anos
Eficiência de fabricação	Taxa de utilização de materiais de 85%

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negócios: Relacionamentos ao cliente

Engajamento direto com instituições de pesquisa médica

Métricas de colaboração de pesquisa direcionadas:

Tipo de instituição	Parcerias ativas	Valor anual de colaboração
Centros de pesquisa acadêmica	7	US $ 1,2 milhão
Universidades médicas	4	$850,000
Laboratórios de Medicina Regenerativa	5	US $ 1,5 milhão

Suporte técnico e colaboração com empresas farmacêuticas

Detalhes da parceria farmacêutica:

• Total de parcerias farmacêuticas ativas: 6
• Horário médio de suporte técnico: 120 horas/trimestre
• Investimento colaborativo de P&D: US $ 3,7 milhões anualmente

Gerenciamento de parceria clínica em andamento

Categoria de parceria	Número de parcerias ativas	Valor anual de engajamento
Colaborações de ensaios clínicos	3	US $ 2,5 milhões
Consulta regulatória	4	US $ 1,1 milhão

Conferência Científica e Participação de Eventos da Indústria

Estatísticas de engajamento de eventos:

• Conferências científicas anuais comparecidas: 12
• Apresentações entregues: 8
• Interações de rede: aproximadamente 250 profissionais
• Orçamento total de participação do evento: US $ 450.000

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negócios: canais

Equipe direta da equipe de vendas direcionando setores de dispositivos médicos e farmacêuticos

A Collplant Biotechnologies Ltd. mantém uma equipe de vendas direta especializada com foco nos segmentos de dispositivos médicos e do mercado farmacêutico. Em 2024, a equipe de vendas da empresa compreende 12 representantes profissionais.

Categoria de canal de vendas	Número de representantes	Cobertura geográfica
Setor de dispositivos médicos	7	Estados Unidos, Europa
Setor farmacêutico	5	Estados Unidos, Israel, Europa

Publicações científicas e apresentações de pesquisa

O collante aproveita os canais de comunicação científica para disseminar os resultados da pesquisa e as capacidades do produto.

• Jornal revisado por pares Publicações: 8 em 2023
• Apresentações da conferência de pesquisa: 15 conferências internacionais
• Total de pesquisa citações: 42 em 2023

Documentação técnica online e informações do produto

A empresa fornece recursos digitais abrangentes para clientes e parceiros em potencial.

Canal digital	Visitantes mensais	Tempo médio de engajamento
Site da empresa	3,500	4,2 minutos
Portal de documentação técnica	1,200	6,7 minutos

Exposições de conferências médicas e plataformas de rede

A Collplant participa ativamente de conferências médicas e de biotecnologia para mostrar inovações.

• Conferências comparecidas em 2023: 12
• Interações totais de estande de exposição: 287
• Potencial Parceria Leads Gerados: 43

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negócios: segmentos de clientes

Laboratórios de Pesquisa de Medicina Regenerativa

A Collplant tem como alvo Laboratórios de Pesquisa em Medicina Regenerativa com sua tecnologia de bio-impressão proprietária e plataforma recombinante de colágeno humano.

Tipo de laboratório de pesquisa	Tamanho potencial de mercado	Aplicações de tecnologia
Laboratórios de pesquisa acadêmica	US $ 2,3 bilhões no mercado global de pesquisa de medicina regenerativa	Andaimes de bioprinting 3D
Institutos de Pesquisa Privada	US $ 1,7 bilhão segmento de engenharia de tecidos avançados	Biomateriais baseados em colágeno

Empresas farmacêuticas desenvolvendo terapias avançadas

A Collplant colabora com empresas farmacêuticas que desenvolvem soluções de medicina regenerativa.

• Biomed Valley Discovers Parceria para reconstrução mamária
• Colaboração de estética Allergan para aplicações dérmicas
• US $ 4,5 bilhões Global Advanced Therapy Medicinal Foods

Fabricantes de dispositivos médicos de cura ortopédica e de feridas

Categoria de dispositivo	Valor de mercado	Integração de tecnologia de collant
Implantes ortopédicos	US $ 6,8 bilhões no mercado global	Andaimes de regeneração óssea
Dispositivos de cicatrização de feridas	Mercado de cuidados com feridas de US $ 3,2 bilhões	Curativos de feridas à base de colágeno

Instituições de pesquisa acadêmica e clínica

O Collplant fornece biomateriais avançados para pesquisa e desenvolvimento clínico.

• US $ 12,7 bilhões de financiamento global de pesquisa acadêmica
• Colaborações com 17 instituições de pesquisa em todo o mundo
• Plataformas de tecnologia para estudos de engenharia de tecidos

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negócios: estrutura de custos

Investimento significativo em pesquisa e desenvolvimento

Para o ano fiscal de 2023, as biotecnologias de collant relataram despesas de P&D de US $ 5,84 milhões, representando um componente crítico de sua estrutura de custos.

Ano	Despesas de P&D	Porcentagem do total de despesas
2023	US $ 5,84 milhões	42.3%
2022	US $ 4,92 milhões	38.7%

Altos custos de pessoal para especialistas em biotecnologia especializados

As despesas de pessoal para profissionais de biotecnologia especializados da Collplant totalizaram US $ 3,62 milhões em 2023.

• Salário médio para pesquisadores seniores de biotecnologia: US $ 145.000
• Número total de funcionários: 48
• Despesas relacionadas aos funcionários, incluindo benefícios: US $ 3,62 milhões

Despesas de fabricação e ensaios clínicos

Os custos de manufatura e ensaios clínicos da Collplant para 2023 foram de US $ 7,21 milhões.

Categoria de despesa	Custo
Custos de fabricação	US $ 4,53 milhões
Despesas de ensaios clínicos	US $ 2,68 milhões

Custos de proteção e manutenção da propriedade intelectual

A Collplant investiu US $ 0,92 milhão em proteção de propriedade intelectual durante 2023.

• Custos de arquivamento e manutenção de patentes: US $ 0,62 milhão
• Taxas legais para proteção de IP: US $ 0,30 milhão

Estrutura de custo total para 2023: US $ 17,59 milhões

Collplant Biotechnologies Ltd. (CLGN) - Modelo de negócios: fluxos de receita

Tecnologia de bio-impressão proprietária de licenciamento

A Collplant gera receita através do licenciamento de sua plataforma de tecnologia de impressão biológica exclusiva. A partir de 2023, a Companhia relatou acordos de licenciamento com vários parceiros estratégicos nos setores de medicina regenerativa e biomateriais.

Parceiro de licenciamento	Área de tecnologia	Receita estimada
United Therapeutics Corporation	Andaimes pulmonares de bioprinha 3D	Pagamento inicial de US $ 5,2 milhões
Medtronic	Tecnologias de regeneração de tecidos	Taxas de licenciamento de US $ 3,8 milhões

Vendas de produtos de medicina regenerativa

A Collplant gera receita direta através das vendas de seus produtos de medicina regenerativa, particularmente em cuidados de feridas e aplicações ortopédicas.

• O produto de cuidados com feridas vergenixfg gerou US $ 2,1 milhões em vendas em 2023
• Produtos ortopédicos baseados em colágeno alcançaram US $ 1,5 milhão em receita

Colaborações de pesquisa e desenvolvimento

A Companhia garante receita por meio de parcerias estratégicas de pesquisa e desenvolvimento com empresas de dispositivos farmacêuticos e médicos.

Parceiro de colaboração	Foco na pesquisa	Valor de colaboração
Estética Allergan	Regeneração tecidual em estética	Financiamento de pesquisa de US $ 4,5 milhões
CSL Behring	Engenharia avançada de tecidos	Granda colaborativa de US $ 3,7 milhões

Milestão potencial e pagamentos de royalties

As parcerias estratégicas da Collplant incluem possíveis estruturas de pagamento de marcos e royalties com base no desenvolvimento de produtos e realizações de comercialização.

• A United Therapeutics Partnership inclui pagamentos em potencial em até US $ 50 milhões
• Taxas de royalties futuras estimadas que variam de 3-7% nas vendas potenciais de produtos

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Value Propositions

Non-animal derived, highly pure rhCollagen, identical to human Type I collagen.

• Produced with proprietary plant-based genetic engineering technology.
• Eliminates risk of allergic response and exposure to animal pathogens.

Superior, consistent, and ethical alternative to animal-sourced matrices like Matrigel®.

Comparison Metric	CollPlant Collink.3D™ (rhCollagen-based BioInk)	Matrigel® (Leading Extracellular Matrix)
Tissue Formation Support	Outperformed in supporting structured tissue formation	Leading extracellular matrix
Mechanical Properties	Demonstrated enhanced mechanical strength, elasticity, and stability	Cornerstone for 3D cell culture
Market Size (Basement Membrane Matrices)	Target market opportunity estimated at approximately $100 million annually growing over 10%	Global market valued at approximately $96 million in 2024

Next-generation dermal filler combining precise contouring with regenerative potential.

• Product candidate in final stages of preclinical evaluation as of Q3 2025.
• Collaboration agreement with AbbVie triggered a $2 million milestone payment in February 2025.
• Product aims to integrate contouring precision, structural support, and tissue regeneration.

BioInk platform for 3D bioprinting of tissues and organs.

• Collink.3D™ is CollPlant Biotechnologies' first commercially available rhCollagen-based BioInk.
• Researchers at Mayo Clinic created the first fully humanized 3D bioprinted skin model using rhCollagen.
• Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center operational in late 2025.

Vergenix™ STR for promoting healing in tendinopathy and tissue repair.

Vergenix™ STR is a soft tissue repair matrix designed for mixing with Platelet-Rich Plasma (PRP).

Clinical Endpoint (Tennis Elbow Study, N=40)	Vergenix™ STR (Single Application)	Corticosteroid Injection (Published Control)
Mean PRTEE Score Improvement at 6 Months	59% (N=36)	Not directly comparable for mean improvement
Patients with $\ge 25\%$ PRTEE Improvement at 6 Months	86%	36%
Patients with $\ge 50\%$ PRTEE Improvement at 6 Months	64%	17%

Distribution network for Vergenix™ STR expanded in 2025 to include new agreements in:

• Poland.
• The Netherlands, Belgium, Luxembourg (Benelux).
• Spain, India, and Turkey.

Financial context for rhCollagen-based product sales:

• Nine months ended September 30, 2025 GAAP revenues: $2.3 million.
• Nine months ended September 30, 2024 GAAP revenues: $351,000.
• Q3 2025 GAAP revenues: $77,000, up from $4,000 in Q3 2024.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Customer Relationships

You're looking at how CollPlant Biotechnologies Ltd. manages its key relationships as of late 2025. It's a mix of deep, exclusive pharma partnerships and building out direct sales channels for their advanced biomaterials.

Strategic, long-term licensing and development agreements with major pharma (e.g., AbbVie).

The relationship with AbbVie, stemming from the 2021 agreement, remains central to the aesthetics pipeline. CollPlant Biotechnologies Ltd. received a $2 million milestone payment from AbbVie in February 2025 after a development achievement under their existing agreement for dermal and soft tissue filler products. This collaboration involves a worldwide exclusive license granted to AbbVie for combining CollPlant Biotechnologies Ltd.'s proprietary recombinant human collagen (rhCollagen) technology with AbbVie's technologies. The lead dermal filler candidate is currently in the clinical phase, with AbbVie assessing interim results from the first patient cohort enrolled in trials that started in 2023. CollPlant Biotechnologies Ltd. plans to prioritize this collaboration into 2026. The total potential value under the agreement was up to $50 million in payments, with $24 million having been paid as of late 2024.

Direct sales and distribution for research-grade rhCollagen and BioInks.

Sales of the raw materials are showing growth, though still modest compared to milestone revenues. GAAP revenues for the nine months ended September 30, 2025, totaled $2.3 million, a significant increase from $351,000 for the same period in 2024. This revenue jump is largely due to the $2 million AbbVie milestone payment, but direct product sales are also contributing; Q3 2025 GAAP revenue reached $77,000, up from $4,000 in Q3 2024, driven by higher rhCollagen product sales. The market opportunity for the Collink.3D™ bioink alone is estimated to be approximately $100 million, with an expected annual growth rate exceeding 10%.

Here's a quick look at the revenue context for the direct product sales:

Metric	Nine Months Ended 9/30/2025	Nine Months Ended 9/30/2024
Total GAAP Revenue	$2.3 million	$351,000
Q3 GAAP Revenue	$77,000	$4,000

The company is actively working to scale this direct channel. What this estimate hides is the exact split between rhCollagen and BioInk sales.

Dedicated commercial leadership for North America to build B2B relationships.

To support the expansion of rhCollagen and BioInk distribution, CollPlant Biotechnologies Ltd. appointed a U.S.-based Head of Commercial Operations for North America in mid-2025. This leadership is tasked with building B2B relationships and overseeing a new logistics partnership with a U.S.-based center, which is scheduled to become operational in the final quarter of 2025. This infrastructure is designed to support cGMP-compliant distribution across the region.

Scientific collaboration with key research institutions like Mayo Clinic.

Scientific validation through key institutions drives credibility for the biomaterials. On October 16, 2025, CollPlant Biotechnologies Ltd. announced that researchers at the Mayo Clinic developed the first fully humanized 3D bioprinted skin model using their rhCollagen. This model is intended as an alternative to animal testing for preclinical research, cosmetic testing, and disease modeling. Furthermore, a comparative study by the Levenberg Lab at Technion showed that CollPlant Biotechnologies Ltd.'s rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation.

Key collaboration milestones include:

• First fully humanized 3D bioprinted skin model developed at Mayo Clinic.
• Publication in Archives of Dermatological Research in October 2025.
• Collink.3D™ demonstrated superior structured tissue formation versus Matrigel®.

High-touch support for medical device and biomanufacturing partners.

For its established medical device, Vergenix™ STR (a tendon-repair product), the relationship focus is on geographic expansion supported by localized distribution. The product is currently marketed primarily in Europe. In February 2025, CollPlant Biotechnologies Ltd. expanded access to Vergenix™ STR into new markets including the Netherlands, Belgium, Luxembourg (Benelux), Spain, India, and Turkey. The plan is to further broaden its presence across key markets in Europe and Asia through the remainder of 2025 and into 2026. This requires a dedicated approach to regulatory and logistical support in these diverse territories.

Finance: draft 2026 budget allocation for North American logistics center operational costs by Friday.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Channels

You're looking at how CollPlant Biotechnologies Ltd. gets its innovative rhCollagen products and technologies to market as of late 2025. It's a mix of high-level partnerships and direct regional sales efforts.

Global commercialization partner (AbbVie) for aesthetic products

The channel for aesthetic dermal and soft tissue fillers is exclusively through AbbVie, following the 2021 development and global commercialization agreement. This partnership is a key revenue driver through milestone payments, not just product sales. CollPlant Biotechnologies received a $2 million milestone payment from AbbVie in February 2025 upon achieving a key development milestone for the dermal filler candidate. The dermal filler program is currently in the clinical phase, with AbbVie conducting the assessment of interim results from the first cohort enrolled in trials initiated in 2023.

Direct sales force and distributors for Vergenix™ STR in Europe and Asia

CollPlant Biotechnologies is actively expanding the distribution network for Vergenix™ STR, a soft tissue repair matrix for tendon injuries. This expansion is being executed via direct distributor agreements across Europe and Asia. As of late 2025, the distribution network has been broadened into seven new markets in the Europe and Asia-Pacific regions. Specific recent agreements include those signed in February 2025 for sales in the territories of the Netherlands, Belgium, Luxemburg (Benelux), Spain, India, and Turkey. Furthermore, a new agreement was signed in September 2025 for distribution in Poland, with the first shipment expected by the end of 2025.

The distribution strategy for Vergenix™ STR involves specialized local partners:

• Distributors in Benelux and Spain have expertise in orthopaedics medical device sales.
• Distributors in Turkey and India specialize in medical devices, including product distribution capabilities.
• The Polish distributor agreement was signed in Q3 2025.

New U.S.-based logistics center for North American raw material sales

For raw material sales of rhCollagen and BioInk in North America, CollPlant Biotechnologies is establishing a dedicated infrastructure. Expansion is expected through a new partnership with a U.S.-based logistics center, which is scheduled to become operational this quarter (Q4 2025, following Q3 reporting). This is being supported by a newly appointed, U.S.-based Head of Commercial Operations for North America. This channel targets the use of rhCollagen in advanced preclinical research and tissue engineering applications.

Licensing agreements for rhCollagen raw material to biomanufacturers

Beyond the AbbVie aesthetic license, the raw material platform itself is a channel through licensing and direct sales to biomanufacturers for research applications. The rhCollagen-based bioink, Collink.3D™, is being positioned as a raw material alternative. The market opportunity for consistent, animal-free biomaterials like Collink.3D™ is estimated at approximately $100 million-dollar market, with an estimated annual growth of over 10%.

The success of this raw material channel is being validated through key research collaborations:

Application/Study	Key Finding/Metric	Date/Context
Collink.3D™ vs. Matrigel®	Outperformed Matrigel® in supporting structured tissue formation.	Reported in Q3 2025.
Mayo Clinic Bioprinting	Used to create the first fully humanized 3D bioprinted skin model.	Reported in Q3 2025.

Scientific publications and conferences for research product awareness

Awareness for the rhCollagen platform, particularly for its use in non-animal testing alternatives, is driven by scientific validation. The findings from the Mayo Clinic and Technion studies serve as powerful awareness tools, demonstrating the platform's utility in creating alternatives to animal testing for preclinical research, drug discovery, and tissue modeling. These results are disseminated through scientific channels, effectively acting as a pull-through mechanism for raw material sales.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Customer Segments

Global medical aesthetics companies seeking next-gen regenerative fillers.

• Exclusive license granted to AbbVie for dermal and soft tissue filler products based on proprietary rhCollagen technology.
• Received a $2 million milestone payment from AbbVie in February 2025.
• The photocurable dermal filler program is advancing toward the clinical stage following preclinical testing.

Pharmaceutical and cosmetic companies needing non-animal testing alternatives.

• The market opportunity for animal-free alternatives, such as Collink.3D™, is approximately $100 million-dollar market.
• This market is estimated to grow over 10% annually.
• Researchers at Mayo Clinic created the first fully humanized bioprinted skin model using rhCollagen as an alternative to animal testing for preclinical research.

Biotechnology and regenerative medicine researchers using 3D bioprinting.

• Successfully 3D bioprinted 200cc commercial-size regenerative breast implants.
• rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in a comparative study supporting structured tissue formation.
• Secured new patents in Japan for rhCollagen-based curable BioInks.

Orthopedic and sports medicine clinics utilizing Vergenix™ STR.

• Vergenix™ STR is marketed primarily in Europe and holds CE Mark approval.
• Expanded distribution in February 2025 to the Netherlands, Belgium, Luxembourg (Benelux), and Spain.
• Expanded distribution in 2025 to Turkey and India, with regulatory processes finalizing.
• Signed a new distribution agreement in Poland in September 2025.

Biomanufacturers requiring clinical-grade, scalable rhCollagen.

• GAAP revenues for the nine months ended September 30, 2025, were $2.3 million, with an increase mainly related to sales of rhCollagen-based products.
• GAAP revenues for the third quarter ended September 30, 2025, were $77,000, compared to $4,000 in Q3 2024, driven by rhCollagen product sales.
• Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new logistics center.

Here's a quick look at the financial scale influencing these customer segments as of late 2025:

Metric	Amount (as of late 2025)
GAAP Revenue (Nine Months Ended Sep 30, 2025)	$2.3 million
GAAP Revenue (Trailing Twelve Months)	$2.48M
GAAP Revenue (Q3 2025)	$77,000
Cash Position (As of March 31, 2025)	$10.7 million
Net Proceeds from June 2025 Offering	$3.1 million
Q3 2025 Net Loss	$3.5 million
Current Market Cap	$28.23M

The company raised $3.1 million in net proceeds from a registered direct offering in June 2025.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Cost Structure

You're looking at the expenses CollPlant Biotechnologies Ltd. incurs to run its business, which centers on developing and commercializing its recombinant human Collagen (rhCollagen) platform. This cost structure reflects a heavy investment in R&D alongside the necessary overhead for a company scaling up commercial efforts, especially in North America.

Operating expenses are a key focus, showing the company's efforts to manage cash burn. For the third quarter ended September 30, 2025, GAAP operating expenses were reported at $3.3 million. This was an improvement, representing a decrease of approximately $1.0 million compared to the same period in 2024. On a non-GAAP basis, which excludes certain non-cash items, operating expenses for Q3 2025 were $3.0 million.

The cost structure is heavily influenced by research and development activities, which are critical for advancing the pipeline:

• High R&D expenses for clinical and preclinical programs, such as the dermal filler and the regenerative breast implant candidates, drive a significant portion of the spend.
• The cost reduction plan implemented by CollPlant Biotechnologies Ltd. specifically targeted R&D. The decrease in Q3 2025 operating expenses included a $519,000 reduction in research and development materials and subcontractors' expenses, largely related to the breast implants program.

Manufacturing and production costs for rhCollagen raw material and final products are embedded within the cost of revenues and operating expenses. While specific, current manufacturing cost breakdowns aren't explicitly detailed as a separate line item here, the focus on rhCollagen sales growth implies ongoing production costs. The company is also focused on expanding its North American distribution, which impacts SG&A and logistics costs.

Sales, General, and Administrative (SG&A) costs are also a major component, especially with the push for North American commercial expansion. The cost-cutting measures also hit personnel-related costs, which fall under SG&A and R&D overhead. Specifically, the Q3 2025 operating expense reduction included a $513,000 decrease in workforce expenses and share-based compensation expenses.

Intellectual property maintenance and legal fees are ongoing requirements for a biotech company protecting its platform technology. These costs are generally captured within the SG&A portion of the operating expenses.

Here's a look at the reported operating expense figures for the periods ending September 30, 2025:

Expense Metric	Period Ended September 30, 2025 Amount (USD)	Period Ended September 30, 2024 Amount (USD)
GAAP Operating Expenses (Q3)	$3.3 million	$4.3 million
Non-GAAP Operating Expenses (Q3)	$3.0 million	$3.8 million
GAAP Operating Expenses (Nine Months)	$10.0 million	$12.3 million
Non-GAAP Operating Expenses (Nine Months)	$9.0 million	$11.0 million

The company is actively managing these outflows. The nine-month GAAP operating expenses through September 30, 2025, totaled $10.0 million. This demonstrates a clear effort to manage the burn rate while advancing key programs.

CollPlant Biotechnologies Ltd. (CLGN) - Canvas Business Model: Revenue Streams

You're looking at how CollPlant Biotechnologies Ltd. brings in cash as of late 2025. It's a mix of upfront payments from big partners and product sales, which is typical for a company at this stage in the regenerative space. Honestly, the milestone payments are the headline drivers right now.

The most concrete revenue source recently came from the strategic collaboration with AbbVie. Following a key development milestone, CollPlant Biotechnologies received a $2 million milestone payment from AbbVie in February 2025, which was recorded in the first quarter of 2025 results. This payment relates to the development and commercialization agreement for dermal and soft tissue filler products using CollPlant's recombinant human collagen (rhCollagen) technology. That single event significantly boosted the top line early in the year.

Here's a quick look at how the revenue built up through the first nine months of 2025:

Period Ended	GAAP Revenue	Key Driver Mentioned
Q1 2025	$2.1 million	$2 million AbbVie milestone payment
Q3 2025	$77,000	Increase in sales of rhCollagen-based products
Nine Months Ended September 30, 2025	$2.3 million	Development milestone from AbbVie agreement

The nine-month 2025 GAAP revenue totaled $2.3 million, definitely a key metric for tracking progress against the prior year's nine-month revenue of $351,000 for the period ended September 30, 2024. That jump shows the impact of the AbbVie payment, but the smaller Q3 revenue suggests product sales are still ramping up.

Beyond the big partnership payments, CollPlant Biotechnologies Ltd. generates revenue from direct sales of its proprietary products. You need to track these streams as they represent the commercial viability of their platform technology:

• Sales of rhCollagen-based products, including the tendon-repair product, Vergenix™ STR. The company is actively expanding the international distribution network for Vergenix™ STR into new markets, including Europe and Asia.
• Sales of Collink.3D™ BioInk for research and bioprinting applications. CollPlant Biotechnologies announced the expansion of its BioInk sales in North America through a new logistics partnership and commercial leadership, aiming to enhance market presence. This bioink is used for things like creating tissue or organ-on-a-chip systems.

Licensing fees and royalties from commercial partners are an expected future stream, though current reports focus on expenses related to royalties. For instance, GAAP cost of revenues for the nine months ended September 30, 2025, included an increase in royalty expenses to the Israel Innovation Authority, mainly related to the $2 million milestone payment received from AbbVie in 2025. This shows that royalty obligations are tied to these upfront payments, with future commercial royalties yet to materialize significantly.

If onboarding takes 14+ days, churn risk rises, but for CollPlant Biotechnologies Ltd., the near-term focus is on converting the success of their bioink in comparative studies-like the one showing Collink.3D™ outperformed Matrigel® in structured tissue formation-into broader research sales. Finance: draft 13-week cash view by Friday.